X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Medicare Part D cliff ahead

By Juliet Johnson  |    June 21, 2018
Medicare Part D has been providing seniors with access to prescription drug coverage that meets their needs for more than a decade. Today, more than 42 million people are enrolled in Part D and 90...   Read More

Aspen Spotlight Health: Discussing the forefront of innovation

By Katie Koziara  |    June 21, 2018
For the second year in a row, PhRMA is proud to participate in Aspen’s Spotlight Health Conference. As the opening session of Aspen Ideas Festival, Spotlight Health welcomes over 1,500 experts and...   Read More

Patients with a deductible have seen their out-of-pocket costs for brand medicines increase 50 percent since 2014

By Holly Campbell  |    June 20, 2018
Spending on medicines is growing at the slowest rate in years, but according to a new IQVIA Institute for Human Data Science article, at the pharmacy, commercially insured patients with a...   Read More

Celebrating U.S. innovation as USPTO issues the 10 millionth patent

By Nicole Longo  |    June 19, 2018
The U.S. patent system has supported innovation and discovery dating back to the founding of our nation and the signing of the U.S. Constitution, encouraging Americans to continue to search for...   Read More

Long-awaited FDA guidance addresses one key obstacle to value-based contracting

By Jim C. Stansel  |    June 19, 2018
As part of the broader shift away from paying for volume to paying for value in health care, payors are increasingly pursuing value-based or results-based contracts with biopharmaceutical...   Read More

ICYMI - Analysis finds higher outpatient drug spending at 340B hospitals

By Nicole Longo  |    June 18, 2018
Did you know 340B hospitals prescribe more medicines or more expensive medicines? A recent analysis by Milliman, commissioned by PhRMA, found hospitals participating in the 340B drug pricing...   Read More

Part D cliff looms for seniors, as program stability could be in jeopardy

By Juliet Johnson  |    June 18, 2018
For more than a decade, Medicare Part D has successfully provided seniors comprehensive prescription drug coverage that meets their needs, while its market-based structure has kept overall program...   Read More

Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill

By Andrew Powaleny  |    June 14, 2018
This week, the new era of medicine was brought to Capitol Hill in Washington, DC when 55 biopharmaceutical researchers from 20 PhRMA member companies held 79 meetings with members of Congress and...   Read More

Diversity of thought fuels next generation of breakthroughs

By Andrew Powaleny  |    June 7, 2018
This month, PhRMA is proud to join with our member companies to celebrate Lesbian, Gay, Bisexual and Transgender (LGBT) PRIDE Month.     Read More

New analysis shows that more medicines worldwide are available to U.S. patients

By Kevin Haninger  |    June 5, 2018
In the past year, we have seen revolutionary new treatments become available to patients in the United States for cancer and other debilitating diseases. A new analysis puts in perspective the...   Read More

New analysis shows that HTA organizations may frequently restrict access to cancer treatments

By Randy Burkholder  |    June 1, 2018
In health care, who should decide value? In many industrialized countries with single-payer health systems, the answer is “the government.” A new analysis by Avalere illustrates the negative...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates